CRISPR Therapeutics and Sirius Therapeutics announced that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI (FXI) small interfering RNA (siRNA) therapy. This milestone follows the European Medicines Agency (EMA) authorization to initiate the Phase 2 trial for thromboembolic disorders. The dosing of the first patient signifies the advancement of this partnered program into a later stage of clinical development.
The collaboration with Sirius Therapeutics expands CRISPR Therapeutics' therapeutic portfolio into RNA-based medicines, complementing its gene-editing efforts. SRSD107 has previously demonstrated promising Phase 1 clinical data, including peak reductions in FXI activity exceeding 93% and sustained efficacy for up to six months post-dosing. Advancing into Phase 2 is a critical step in evaluating the therapy's efficacy and safety in a larger patient population.
This operational milestone is important for the continued development of SRSD107, which aims to offer a differentiated approach to reducing thrombotic events with minimal bleeding risk. Successful progression through clinical trials is essential for bringing this potential new therapy to market and realizing the value of the strategic partnership.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.